menu
    • menu
    [{"orgOrder":0,"company":"VectorBuilder","sponsor":"Lantu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"LTGT06","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectorBuilder \/ Lantu Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"VectorBuilder \/ Lantu Biopharma"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"AAV-Based Gene Therapy","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"VectorBuilder \/ Stand Up Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuilder \/ Stand Up Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by VectorBuilder

    Menu

    VectorBuilder

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-Based Gene Therapy

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : Stand Up Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Stand Up Therapeutics Signed with VectorBuilder for World's First Gene Therapy Supply for Paraplegia Patient

                            Details : STUP-001 (AAV-based gene therapy), the innovative GT medication, unties the knot for spinal cord injured patient through motor sensory neuron reprogramming technology. Cell fate conversion using virus transduction system is of great interest in the field...

                            Brand Name : STUP-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 29, 2022

                            Lead Product(s) : AAV-Based Gene Therapy

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : Stand Up Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : Legend Capital

                            Deal Size : $56.1 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            VectorBuilder Secures CNY410M in Series C Round

                            Details : The company intends to use the funds to promote the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 20, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : Legend Capital

                            Deal Size : $56.1 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            VectorBuilder

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTGT06

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Lantu Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            VectorBuilder Supports First Gene Therapy Trial for Menkes Disease

                            Details : The adeno-associated virus (AAV) based drug, LTGT06, was developed by Lantu with crucial support from VectorBuilder. The trial subject was a three-year-old boy whose father gained worldwide attention for not giving up on his son.

                            Brand Name : LTGT06

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 23, 2022

                            Lead Product(s) : LTGT06

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Lantu Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth